电化学发光免疫法识别狼疮肾炎低丰度尿液生物标志物
本研究利用电化学发光(ECL)平台在独立队列中筛查狼疮肾炎(LN)患者尿液低丰度蛋白标志物,发现活动性LN患者尿液中IL-7、IL-12p40、IL-15、IP-10和TARC水平显著升高,且与肾脏SLEDAI及医生整体评估相关。ECL可检测ELISA无法检出的低丰度尿液标志物。
要点
- 活动性LN患者尿液中IL-7、IL-12p40、IL-15、IP-10和TARC水平显著升高。
- 上述5种尿液蛋白与肾脏SLEDAI和医生整体评估良好相关(R > 0.67,P < 0.05)。
- ECL可检测ELISA无法检出的低丰度尿液生物标志物。
核心结论
- 尿液IL-7、IL-12p40、IL-15、IP-10和TARC水平可能是LN有用的诊断工具。
研究设计与样本
- 随后开发定制5-plex ECL panel,用于检测140份尿液样本(44例活动性LN、41例非活动性SLE、28例健康对照、27例其他肾脏疾病)。
主要发现
- 队列1中活动性LN患者尿液有17种蛋白水平较非活动性SLE和健康对照升高(双侧Mann-Whitney U检验P < 0.05),队列2中有9种类似升高。
- IL-7、IL-12p40、IL-15、IP-10和TARC被选为进一步验证,这些蛋白用ELISA无法检测到。
- 定制5-plex ECL panel验证显示,活动性LN患者尿液IL-7、IL-12p40、IL-15、IP-10和TARC水平再次显著高于非活动性SLE和健康对照,且与肾脏SLEDAI和医生整体评估良好相关(R > 0.67,P < 0.05)。
- 5种尿液蛋白在LN中较其他慢性肾脏疾病对照更常升高,但整体组间差异仅尿IL-7和IL-15达到显著性。
关键数值与推荐
- 活动性LN定义:肾脏SLEDAI >0;非活动性SLE定义:肾脏SLEDAI 0。
- 队列1中17种尿液蛋白升高(P < 0.05),队列2中9种升高(P < 0.05)。
- 验证的5种蛋白与肾脏SLEDAI和医生整体评估相关R > 0.67,P < 0.05。
临床怎么用
- 尿液IL-7、IL-12p40、IL-15、IP-10和TARC可作为活动性LN的潜在诊断标志物。
- ECL平台可用于检测ELISA无法检出的低丰度尿液生物标志物。
局限性
- 其他慢性肾脏疾病对照中仅尿IL-7和IL-15的组间差异达到显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the utility of a sensitive platform using electrochemiluminescence (ECL) for the identification of low-abundance urinary protein biomarkers in lupus nephritis (LN). METHODS: Forty-eight urine samples were obtained from subjects in 2 independent cohorts, each consisting of 3 groups (matched for age, sex, and race) of 8 patients with active LN (renal Systemic Lupus Erythematosus Disease Activity Index [SLEDAI] >0), 8 patients with inactive SLE (renal SLEDAI 0), and 8 healthy controls. Samples were tested using a preexisting 40-plex ECL panel. A custom 5-plex ECL panel was then developed for further validation studies and used to test 140 urine samples (from 44 patients with active LN, 41 patients with inactive SLE, 28 healthy controls, and 27 patients with other kidney diseases). RESULTS: Levels of 17 urinary proteins were elevated (P < 0.05 by 2-tailed Mann-Whitney U test) in samples from patients with active LN compared to samples from patients with inactive SLE and healthy controls in cohort 1, while 9 were similarly elevated in cohort 2. Of these, interleukin-7 (IL-7), IL-12p40, IL-15, interferon-γ-inducible protein 10 (IP-10), and thymus and activation-regulated chemokine (TARC) were chosen for further validation. These 5 proteins were undetectable by enzyme-linked immunosorbent assay (ELISA). Hence, a custom 5-plex ECL panel was developed and used to validate the results from the initial 40-plex screening panel. Urinary IL-7, IL-12p40, IL-15, IP-10, and TARC levels were again significantly elevated in patients with active LN compared to those with inactive SLE and healthy controls, and correlated well with the renal SLEDAI and physician's global assessment of disease activity (R > 0.67, P < 0.05). All 5 urinary proteins were more frequently elevated in LN compared to controls with other chronic kidney diseases, although overall group differences attained significance only for urinary IL-7 and IL-15. CONCLUSION: Urinary levels of IL-7, IL-12p40, IL-15, IP-10, and TARC are potentially useful diagnostic tools in LN. The use of ECL assays may allow detection of urinary biomarkers that are below ELISA detection limits.
引用
- Stanley S, Mok CC, Vanarsa K, et al. Identification of Low-Abundance Urinary Biomarkers in Lupus Nephritis Using Electrochemiluminescence Immunoassays. Arthritis Rheumatol. 2019. PMID: 30618193. doi:10.1002/art.40813
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。